Defecetive Drugs: adrugrecall.com
NEWSLETTER
Sign up for our newsletter
to receive breaking news about drugs to watch
Contact A Lawyer
Near You
Contact us today for a complimentary consultation with a qualified attorney near you.
COX-2 drugs under review by Europeans following Vioxx recall
-October 25, 2004
Following the Vioxx recall, the European Medicines Agency, the regulator based in London that monitors pharmaceutical safety and consists of a network of 3,000 scientists and experts to conduct studies and make decisions, is now reviewing all COX-2 inhibitor drugs. COX-2 inhibitors are the anti-inflammatory class of drugs that includes Vioxx and Pfizer's Celebrex and Bextra.
The agency is examining COX-2 inhibitors to study its effects on cardiovascular health. After the September 30 Vioxx recall, the safety of the entire class of drugs has been questioned. Twenty-seven million U.S. patients take Celebrex, and although Pfizer has said it is "confident in the long-term cardiovascular safety," some experts believe the cardiovascular effects may be a class-wide effect.
The FDA is also currently reviewing COX-2 drugs. In less than two weeks, Vioxx maker Merck & Co. stunned investors after announcing it had received 300 Vioxx related lawsuits and may not have enough insurance cover to pay claims.
For more information on the vioxx recall, please contact us.
